|D002055||Burnout, Professional NIH||0.33|
|D000077062||Burnout, Psychological NIH||0.23|
|D013315||Stress, Psychological NIH||0.18|
There is one clinical trial.
This single blind, randomized, controlled trial (RCT) evaluates, a nonpharmacological intervention, TM (Transcendental Meditation) for improving burnout (, as measured by self-reporting (survey), physiologic, and neuro-functional imaging studies in health care providers (HCPs) when practiced over 3 months' time. The investigators define HCPs as any physician, physician trainee, nurse, physician assistant, nurse practitioner or respiratory therapist. HCPs will be screened by a single-item stress scale and Columbia Suicide Severity Rating Scale (CSSRS) to understand their stress level and exclusion criteria respectively. The Global Severity Index of the Brief Symptom Inventory (BSI)-18 Global Severity score will be used as the primary outcome for pre- and post-TM training (baseline, 1 vs. 3 months). In addition, the investigators will evaluate physiological markers of stress and cardiovascular resiliency such as 1) changes (pre/post-treatment) in heart rate variability (HRV) through wearables, 2) Galvanic Skin Response (GSR) - changes in sweat gland activity that result from changes in an emotional state. fMRI will be performed by the Duke Brain Imaging and Analysis Center (BIAC) on a subset of participants to evaluate changes A specifically developed mobile app will aid data collection as well as reminders for providers to aid compliance for meditation
Description: Changes in brief symptom inventory as evaluated by BSI 18Measure: change in self reported Stress symptoms Time: Baseline, 1 month, 3 months
Description: These will include secondary outcomes as measured by the Connor Davidson Resilience Scale-25 (CD-RISC).Measure: Change in self reported resilience Time: Baseline, 1 month, 3 months
Description: Change in symptoms of depression will be measured by PHQ 9 scaleMeasure: Change in symptoms of depression Time: Baseline, 1 month, 3 months
Description: Change in insomnia symptoms as measured by Insomnia severity Index(ISI)Measure: Change in insomnia symptoms Time: Baseline, 1 month, 3 months
Description: Change in anxiety symptoms as measured by GAD-7Measure: Change in anxiety symptoms Time: Baseline, 1 month, 3 months
Description: change in psychological distress as measured by the Global Severity Index of the Brief Symptom Inventory (BSI)-18 questionnaire.Measure: Change in psychological distress Time: Baseline, 1 month, 3 months
Description: Change in burnout symptoms in HCPs as measured by Maslach Burnout Inventory( MBI)Measure: Change in self reported burnout symptoms Time: Time Frame: Baseline, 1 month, 3 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports